Literature DB >> 14577917

Targeting a retroviral vector in the absence of a known cell-targeting ligand.

Keith Bupp1, Monica J Roth.   

Abstract

An important requirement for many gene therapy applications is to direct therapeutic genes specifically to target cells. Here we describe an improved vector targeting method that does not depend on the use of a known cell-targeting ligand. It entails screening a library of constitutively produced retroviruses with random amino acid substitutions in the cell-targeting region of the envelope proteins for their ability to mediate gene delivery to a target cell. By screening such a library on the ras-transformed 143B human cell line, we have isolated an envelope protein that preferentially targets 143B cells and 293T cells expressing the SV40 T antigen via a novel, unidentified receptor. Furthermore, retroviruses expressing the library-derived envelope protein can be concentrated by centrifugation. This is the first demonstration of a novel concept in vector targeting: the selection of productive retroviral entry via an alternate receptor with modified cellular tropism in the absence of a known cell-targeting moiety. The method is, in principle, applicable even to cells that have not been well characterized, and therefore potentially suitable for targeting many diverse cell types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577917     DOI: 10.1089/104303403322495061

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

1.  Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A.

Authors:  Peter M Mazari; Takele Argaw; Leonardo Valdivieso; Xia Zhang; Katherine T Marcucci; Daniel R Salomon; Carolyn A Wilson; Monica J Roth
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

2.  Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.

Authors:  Christoph A Merten; Jörn Stitz; Gundula Braun; Eric M Poeschla; Klaus Cichutek; Christian J Buchholz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Identification of a retroviral receptor used by an envelope protein derived by peptide library screening.

Authors:  Anindita Sarangi; Keith Bupp; Monica J Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-20       Impact factor: 11.205

Review 4.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

5.  Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor.

Authors:  Peter M Mazari; Daniela Linder-Basso; Anindita Sarangi; Yehchung Chang; Monica J Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

6.  Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries.

Authors:  Keith Bupp; Anindita Sarangi; Monica J Roth
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Role of Cysteines in Stabilizing the Randomized Receptor Binding Domains within Feline Leukemia Virus Envelope Proteins.

Authors:  Leonardo Valdivieso-Torres; Anindita Sarangi; Jillian Whidby; Joseph Marcotrigiano; Monica J Roth
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

9.  MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors.

Authors:  Dai-Tze Wu; Monica J Roth
Journal:  Biomaterials       Date:  2014-07-03       Impact factor: 12.479

10.  A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.

Authors:  Kouki Morizono; Yiming Xie; Gustavo Helguera; Tracy R Daniels; Timothy F Lane; Manuel L Penichet; Irvin S Y Chen
Journal:  J Gene Med       Date:  2009-08       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.